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An imaged-based profiling and analysis systemwas developed to predict clinically effective
synergistic drug combinations that could accelerate the identification of effective multi-
drug therapies for the treatment of triple-negative breast cancer and other challenging ma-
lignancies. The identification of effective drug combinations for the treatment of triple-
negative breast cancer (TNBC) was achieved by integrating high-content screening, compu-
tational analysis, and experimental biology. The approach was based on altered cellular
phenotypes induced by 55 FDA-approved drugs and biologically active compounds, ac-
quired using fluorescence microscopy and retained in multivariate compound profiles. Dis-
similarities between compound profiles guided the identification of 5 combinations, which
were assessed for qualitative interaction on TNBC cell growth. The combination of the
microtubule-targeting drug vinblastine with KSP/Eg5 motor protein inhibitors monastrol
or ispinesib showed potent synergism in 3 independent TNBC cell lines, which was not
substantiated in normal fibroblasts. The synergistic interaction was mediated by an in-
crease in mitotic arrest with cells demonstrating typical ispinesib-induced monopolar
mitotic spindles, which translated into enhanced apoptosis induction. The antitumour ac-
tivity of the combination vinblastine/ispinesib was confirmed in an orthotopic mouse
model of TNBC. Compared to single drug treatment, combination treatment significantlystitute Australia, Lowy Cancer Research Centre, UNSW, PO Box 81, Randwick, NSW, 2031,
855 (mobile).
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M O L E C U L A R O N C O L O G Y 8 ( 2 0 1 4 ) 1 5 4 8e1 5 6 0 1549reduced tumour growth without causing increased toxicity. Image-based profiling and
analysis led to the rapid discovery of a drug combination effective against TNBC in vitro
and in vivo, and has the potential to lead to the development of new therapeutic options
in other hard-to-treat cancers.
ª 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights
reserved.1. Introduction 2. Materials and methodsMulti-drug regimens are the leading treatment for cancers
since single agent chemotherapies often have limited antitu-
mour activity and have been linked to drug resistance
(Ramaswamy, 2007; Zimmermann et al., 2007). The develop-
ment of these treatments has been increasingly laborious
due to the plethora of potential combinations available
(Zinner et al., 2009). Thus, themajority of existing combination
therapieswere developed empirically based on clinical experi-
ence (Borisy et al., 2003; Zimmermann et al., 2007). The discov-
ery of new drug combinations from a system-oriented angle
has only recently received increasing attention. Mathematical
models and computational approaches, such as optimisation
and search algorithms, were successfully applied to hasten
the identification of effective drug combinations (Calzolari
et al., 2008; Wong et al., 2008; Zinner et al., 2009). In addition,
functional interaction models reliably predicted perturbation
effects in signalling pathways and changes required to obtain
a favourable outcome (Nelander et al., 2008). However, in-
depth assessment of identified combinations and translation
to clinical trials remain to be realised.
The development of new and effective combination treat-
ments is crucial to improve the outcome of patients with
aggressive malignancies such as triple-negative breast cancer
(TNBC). This breast cancer subtype is associated with young
patient age and reduced progression-free and overall survival
(Haffty et al., 2006; Liedtke et al., 2008). The dismal clinical
outcome is mainly attributed to intrinsic and acquired drug
resistance, and the absence of key molecular markers of
breast cancer, which provide valuable therapeutic targets
for other breast cancer subtypes (Reis-Filho and Tutt, 2008).
TNBC was found to be generally more responsive to chemo-
therapy than other subtypes (Carey et al., 2007; Liedtke
et al., 2008); however, these therapies remain suboptimal as
patients without complete response have significantly
shorter overall survival (Carey et al., 2007). Hence, the devel-
opment of novel combination chemotherapies for treatment
of TNBC is essential in order to increase patient survival
rates.
The presented study identifies novel drug combinations
based on the integration of high-content screening (HCS),
computational, and experimental biology. HCS facilitated
the automatic extraction of compound-induced phenotypes
from fluorescence images of TNBC cells. Determination of
compound profiles allowed for the identification of compound
pairswith either very similar or distinct phenotypic outcomes,
which were further assessed for synergistic interactions in
in vitro and in vivo models of TNBC.2.1. Cell culture
MDA-MB-231-luc-D3H2LN cells (Caliper, Hopkinton, MA, USA)
were cultured in DMEMmedium supplemented with 10% FBS,
1% L-glutamate, 1% Na-pyruvate, 1% penicillin/streptomycin,
1% non-essential amino acid and 0.1% zeocin. MDA-MB-
231 cells were maintained in DMEM (Invitrogen, Mount Wav-
erley, Australia) supplemented with 10% FCS, 1% L-glutamate,
1% Na-pyruvate, 1% penicillin/streptomycin, and 1% non-
essential amino acid. MDA-MB-468 and BT-549 cells were
grown in RPMI (Invitrogen) containing 10% FCS, which was
additionally plied with 0.023 IU/ml insulin for BT549 cells.
MRC-5 lung fibroblasts were grown in MEM (Invitrogen) sup-
plemented with 10% FCS, 2% sodium bicarbonate, 1% NEAA,
1% sodium pyruvate, and 1% L-glutamine. Cell lines were
grown as monolayers in a humidified atmosphere at 37 C
and in 5% CO2. The ratio of cells to well surface and compound
volume was kept constant in all experiments.
2.2. Compounds
Compounds for HCS (10 mM in DMSO) were purchased from
Sigma (St. Louis, MO, USA) and Tocris bioscience (Ellisville,
MO, USA). Stock solutions of 50 mM monastrol (Tocris Biosci-
ence, Bristol, UK) and 10 mM ispinesib (Selleck, Scoresby, VIC,
Australia) were prepared in DMSO, and stored at 20 C. Clin-
ical grade vinblastine sulphate (1.1 mM) (David Bull Labora-
tories, Melbourne, VIC, Australia) was stored at 4 C. For
further use, compounds were diluted in the respective media.
2.3. Fluorescence staining and image acquisition
MDA-MB-231-luc-D3H2LN cells (5*103 cells/well) were grown
on poly-D-lysine coated black wall 96-well plates prior to com-
pound exposure (0.1, 1.0 and 10 mM). After 24 h immunostain-
ing with multifluorescent markers for DNA, microtubule and
actin following standard methods using the Cellomics HCS
Cytoskeleton Rearrangement Kit (Thermo, Rockford, USA)
was conducted. Briefly, cellswere first fixed andpermeabilized
using formaldehyde (3.7%), before incubation with primary
antibody solution containing DY554-phalloidin and tubulin
primary antibody, followed by incubation with the secondary
antibody solution containing DyLight 649 Goat Anti-Mouse
and DAPI. Fluorescence images were captured using an
Olympus IX81microscope anda 40Xobjective. Images of chan-
nels for DAPI (DNA), DY554 (F-actin), and DyLight 649 (tubulin)
were acquired for at least 4 different positions in wells.
M O L E C U L A R O N C O L O G Y 8 ( 2 0 1 4 ) 1 5 4 8e1 5 6 015502.4. Image segmentation and feature extraction
Image segmentation was conducted as previously described
(Li et al., 2007). In brief, first nuclei segmentation was per-
formed using adaptive thresholding of the DNA channel and
watershed segmentation of distance-transformed images.
Then over-segmentation was corrected and dead nuclei
were removed. A fuzzy c-means threshold algorithm sepa-
rated the F-actin channel from the background before cyto-
plasm was segmented on basis of nuclei and F-actin
channels. Segmentation results were subsequently assessed
for over-segmentation (Li et al., 2007). Segmented cells were
characterised by phenotypic descriptors from 6 feature cate-
gories (Gabor wavelet, CDF 9/7 wavelet, Haralick co-
occurrence, Zernike moments, region properties and shape
descriptors) yielding feature vectors of 211-dimensions
(Wang et al., 2009). Features were mapped into a matrix and
standardized to a mean of zero and standard deviation of
unity to account for different feature scales.2.5. Multivariate image-based compound profiling
Compound-induced phenotypic changes entailed a discrep-
ancy between treated and untreated cell populations in the
multidimensional feature space. A support vector machine
(SVM) was used to compute optimal hyperplanes to separate
these populations (Loo et al., 2006, 2007). Hyperplanes were
computed using LIBSVM version 2.89 (Chang and Lin, 2001)





In Equation (1), h, i denotes the dot product in the Euclidean
space Rm and bk is the bias term. Depending on the outcome of
the decision function, a cell Ci was either classified to the
group of treated or untreated cells (Loo et al., 2006). The pre-
diction power of the classifier was determined by leave-one-
out, 2-, 5-, and 10-fold cross-validation (CV) experiments.
The orientation of the weight vector Wk described the
compound-induced phenotypic change. Therefore, scaled
weight vectors directed towards the population of the treated
cells were employed as multivariate profiles (Loo et al., 2007).
Final profiles and classification accuracies were computed
from 50 resampling experiments of 2-fold CV, resulting in
152 compound profiles, 55 for concentrations of 0.1 and
1.0 mM, and 42 for 10.0 mM.2.6. Computation of phenotypic dissimilarities
Differences between compound induced phenotypes were
determined using the dissimilarities between profiles:
dpkc ;pk0c ¼ 1
pTkc  pk0cffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
pTkc  pkc
  pTk0c  pk0c
q (2)
In Equation (2), pkc and p0kc denote profiles for compounds kc
and k0c at either the same, or different dosage c with c ¼ 1,2,3.
dpkc ;pK0c
is the profile dissimilarity reflecting the differences be-
tween compound-induced cellular phenotypes (Loo et al.,
2007). Profile pairs were defined as similar or dissimilar if their
dissimilarity was either smaller or larger than their averagedissimilarity to all 152 profiles, respectively. Compound pairs
with dissimilarities fulfilling either of these criteria for more
than half of the profile pairs were considered as combination
candidates with the potential to induce synergy.
2.7. Growth inhibition assays
Treatment effects onMDA-MB-231-luc growth inhibitionwere
assessed using a bioluminescence (BLI) assay. Luciferin was
added to 96-well plates, photon emission measured after 48
and 72 h using the Xenogen Imaging System (IVIS 200), and
data analysed using the software Living Image 3.1 (Perki-
nElmer, Massachusetts, USA). Growth inhibition of other cell
lines was measured on the basis of metabolic activity of cells
using an Alamar blue assay and spectrophotometric analysis.
Briefly, cells were plated in clear transparent 96-well plates at
optimized cell densities of 3e5  103 cells/well for TNBC cell
lines and 3  104 cells/well for MRC-5 cells 24 h prior to treat-
ment. If required DMSO carrier activities exceeding concen-
trations of 0.1% were accounted for.
2.8. Quantification of combination effect
Two different models were used to quantify the effect of com-
binations. The Excess Over the Highest Single Agent (EOHSA)
represents the difference in cell growth inhibition between
the combination treatment and themost effective single com-
pound at the corresponding concentration (Borisy et al., 2003;
Simmons et al., 2014). It was calculated by subtracting the
greater effect induced by the single compounds from that of
the combination, and subsequently visualized using surface
plots.While thismodel focuses on the effect of individual con-
centrations, the combination index (CI) theorem accounts for
the dose response of single drugs to determine the combina-
tion effect (Chou and Talalay, 1984). The resultant equation






In Equation (3), D1 and D2 denote the doses of compound 1
and compound 2 required to reach an effect of x % as single
treatment, while Dx1 and Dx2 are the doses needed in combi-
nation to inhibit x%, respectively (Chou and Talalay, 1984).
Combinations were examined for induction of antagonism
(CI > 1.1), additivity (0.9 < CI < 1.1), synergy (CI < 0.9) and
strong synergy (CI < 0.3).
2.9. Cell cycle analysis and detection of apoptosis
MDA-MB-231 cells were cultured in T25 flasks and treated
with single compounds or the combination for 24 and 48 h
for cell cycle analysis and apoptosis assay, respectively. For
cell cycle analysis, floating and adherent cell populations
were collected and fixed in 70% methanol just before incuba-
tion with propidium iodide (PI) and RNase for 15 min in the
dark. For apoptosis detection, cell pellets containing adherent
and floating cells were resuspended in binding buffer contain-
ing Annexin V-FITC and PI (BD Bioscience, North Ryde, NSW,
Australia) and incubated for 15 min in the dark. DNA content
and apoptosis induction were immediately determined by
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Ryde, Australia). Cell cycle and apoptosis data were analysed
using FlowJo Version 7.6.5 (TreeStar, Inc.).2.10. Immunofluorescence staining of microtubules
MDA-MB-231 cells were seeded on 8-well Permanox Lab-Tek
chamber slides (Applied Biosystems, Mulgrave, Australia)
and treated 24 h later with different concentrations of ispine-
sib, vinblastine or the combination. After 24 h drug incuba-
tion, cells were fixed and permeabilized in 100% methanol at
20 C for 15 min and blocked with 10% FCS for 30 min. Micro-
tubules were then stained with anti-bI-tubulin primary anti-
body (Abcam, Cambridge, UK), followed by Alexa Fluor 488
anti-mouse secondary antibody (Invitrogen, Mount Waverley,
Australia). All slidesweremounted on coverslipswith ProLong
Gold anti-fade reagent containing DAPI (Invitrogen) and
imaged using the 63X oil-immersion objective of an Axiovert
200 M fluorescent microscope coupled to an AxioCamMR3
camera driven by the AxioVision 4.8 software (Carl Zeiss,
North Ryde, Australia). At least 350 cells were counted per
condition to determine the percentage of cells in interphase
and mitosis.2.11. Orthotopic TNBC model
The orthotopic TNBC model was generated by injection of
1*106 MDA-MB-231 cells in 50 ml Matrigel into the mammary
fat pad of female BALB/c nude mice (5e7 weeks old; Charles
River Laboratories, Frederick, MD). Mice were randomized
into 4 groups of 8 mice prior to treatment start. Treatment
was initiated when tumours reached approximately 70 mm3.
Treatment groups were 1) vehicles for Vinblastine (saline)
and Ispinesib (DMSO), 2) Vinblastine (1 mg/kg, in saline) plus
DMSO, 3) Ispinesib (5 mg/kg, in DMSO) plus saline, and 4)
Vinblastine (1 mg/kg, in saline) plus Ispinesib (5 mg/kg, in
DMSO). Treatment was administered i.p. once a week for 3
weeks. Animal weights and tumour size weremeasured twice
aweek. Tumour volumeswere calculated according to the for-
mula 1/2*l*w2. Mice were sacrificed 8 weeks after treatment
start. All experimental procedures involving mice were con-
ducted in accordance with the guidelines of IACUC and the
regulations of the Animal Research and Comparative Medi-
cine Committee of Houston Methodist Research Institute.2.12. Statistical analysis
Computational assignments were done using the student
version of the computing environment Matlab (Version
7.8.0.347 (R2009a)). Statistical analysis of the CI was performed
on results from growth inhibition assays using the software
CalcuSyn version 2.1 (Biosoft, Cambridge, UK) (Chou and
Hayball, 1996). Results from cell cycle and apoptosis assays
were analysed by multiple comparisons between different
treatment groups using one-way ANOVA (GraphPad Prism 5,
GraphPad Software Inc., La Jolla, CA). Multiple comparisons
between different treatment groups from the in vivo study
were conducted using the Student’s t-test (GraphPad Prism
5, GraphPad Software Inc., La Jolla, CA).3. Results
3.1. Acquisition and multivariate analysis of compound-
induced phenotypes in triple-negative breast cancer cells
A workflow was designed to identify synergistic drug combi-
nations in TNBC cells (Figure 1). Thereby, HCS was used to
simultaneously monitor cellular markers (i.e. DNA, F-actin,
and microtubules) in MDA-MB-231-luc cells exposed to 55
FDA-approved drugs and biologically active compounds of 3
concentrations each (0.1, 1 and 10 mM) (Supplementary Table
1). Altogether, 3150 fluorescent images were captured, 1050
for each channel of the DNA-microtubule-actin marker set.
Figure 2A shows MDA-MB-231-luc cells treated with doxoru-
bicin and vinblastine for 24 h in comparison to control cells.
The differentiation between drug-induced phenotypes was
based on cellular features. The treatment shown here altered
features describing cell shape and region properties compared
to control. To allow for the extraction of feature values from
images automatic image processing was conducted using a
seeded watershed algorithm after conversion of RGB images
into gray-scale images (Li et al., 2007). An example for segmen-
tation of cells is shown in Figure 2B. On average, image seg-
mentation resulted in 117  32 and 114  46 delineated cells
for untreated control and compound treatment per view field,
respectively, and a total of 120,361 segmented cells. Extracted
features described region properties, intensity, shape, and
texture characteristics of stained DNA and non-DNA regions
for each cell (Supplementary Table 2) (Wang et al., 2009).
Cellular image-based drug profiling was performed using a
support vector machine (SVM) (Loo et al., 2006, 2007). SVM
yielded best prediction power using 2-fold compared to
leave-one-out, 5- and 10-fold cross-validation (CV) (data not
shown), with average classification accuracies of over 80%
for all 3 compound concentrations (Supplementary Figure 1).
To verify the model’s accuracy, profile dissimilarities of
compounds with the same molecular target were assessed.
For example the majority of dissimilarities between the pro-
files of vinblastine and other compounds targeting the cyto-
skeleton were smaller than the average dissimilarity to all
152 compound profiles (Supplementary Figure 2A). The same
applied to dissimilarities between compounds interacting
with protein synthesis or degradation such as cycloheximide
and emetine (Supplementary Figure 2B). This showed that
profiles were associated with compound targets. Therefore,
dissimilarities reflected the difference between compound-
induced phenotypes andwere used to predict potential syner-
gistic combinations. Experimental evaluation of all pairwise
combinations resulting from 55 compounds would require
1485 combination experiments, testing only one concentra-
tion per compound. To reduce this search space we selected
compound pairs based on the hypothesis that combination
of compounds with either very similar or dissimilar pheno-
types would induce synergistic growth inhibition in TNBC
cells. We used the SVM-derived profiles to select compound
pairs with this characteristic.
Profile dissimilarities smaller or larger than the average
dissimilarity to all 152 compound profiles were considered
similar or dissimilar, respectively. The dot plot in Figure 2C
Figure 1 e Workflow for the imageebased discovery of potential synergistic drug combination. High-content image analysis and compound
profiling using a vector machine formed the basis for comparison of phenotypic outcome due to compound treatment. Combination pairs were
selected for validation if compound profiles proved to be consistently similar or dissimilar. Subsequently, the effect of identified combination pairs on
cell growth inhibition was measured. The assessment of the most promising synergistic combination pair was extended to an in vivomodel of TNBC.
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normalization to the average dissimilarity of all 152 profiles.
Three of the compound pairs displaying similar profiles for
the majority of dose pairs were cytochalasin D/vinblastine,
SB203580/SC560, and cytochalasin D/cycloheximide. For
example, for the compounds cytochalasin D/vinblastine, 8
out of 12 profile pairs had dissimilarities below the average
dissimilarity to all compound profiles, indicating similar
compound-induced phenotypes. Likewise, 7 out of 12 and 12
out of 16 profile pairs had dissimilarities smaller than the
average dissimilarity for SB203580/SC560 and cytochalasin
D/cycloheximide. In sharp contrast, large profile dissimilar-
ities were found for compound pairs vinblastine/doxorubicin
and vinblastine/monastrol. Dissimilarities between vinblas-
tine and doxorubicin profiles all exceeded the average dissim-
ilarities to their profiles, while 8 out of 12 profile pairs
exceeded the average dissimilarities to monastrol and
vinblastine profiles.3.2. Profile dissimilarities identify compounds that
inhibit TNBC cell growth synergistically
After selection of combination pairs with either very similar or
dissimilar profiles, we assessed their effects on growth of
TNBC cells. Surface plots illustrating MDA-MB-231-luc cell
growth indicated that the 5 identified pairwise combinations
vinblastine/cytochalasin D, SB203580/SC560, cycloheximide/cytochalasin D, vinblastine/doxorubicin, and vinblastine/
monastrol inhibited cell growth more potently than single
compounds (Supplementary Figure 3A). Determining the
Excess Over Highest Single Agent (EOHSA) allowed for the
identification of potential synergistic interaction between
compounds and was visualized in surface plots
(Supplementary Figure 3B). Combination effects of selected
compound pairs exceeded the effects of single compounds
for themajority of tested concentrations. Combination effects
were further evaluated using the combination index (CI) theo-
rem (Chou and Talalay, 1984). This analysis confirmed our hy-
pothesis that compound pairs with either very similar or
dissimilar profiles have the potential to synergistically inhibit
TNBC cell growth (Figure 2D). Furthermore, among the five
selected combination pairs, vinblastine/monastrol showed
synergism for more than 80% of dose pairs and displayed
the strongest synergistic interactions.3.3. Vinblastine and KSP/Eg5 inhibitors interact
synergistically in TNBC cells, but not in normal fibroblasts
Since the synergism between vinblastine and monastrol was
the most potent, the validation of combination effects of
vinblastine with KSP/Eg5 inhibitors was further pursued. Due
tomoderate inhibitor activity and poor solubility ofmonastrol,
the development ofmore specificKSP/Eg5 inhibitorswas expe-
dited (Gartner et al., 2005; Sarli et al., 2005). Therefore we used
Figure 2 e Treatmenteinduced alterations of cellular phenotypes, image segmentation, and dissimilarities of compound profiles. A) Fluorescence
staining of microtubule and DNA (channels overlaid), revealing some phenotypic alterations between untreated, 0.1 mM doxorubicin or 0.1 mM
vinblastine treated MDA-MB-231-luc cells after 24 h. B) Delineation of single cells was conducted after conversion of RGB to grayscale images
followed by image-segmentation using a seeded watershed algorithm. C) Dot plot representation of relative profile dissimilarity for compound
pairs. Compound profiles were derived using an SVM. Profile dissimilarities were computed for each concentration pair using a distance measure
and then normalized to the average dissimilarity of all compound profiles. D) Dot plot representation of the combination index (CI) for each
compound pair. CI values were calculated for each concentration pairs following the Chou and Talalay method.
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perimentswith vinblastine. Combination effects ofmonastrol/
vinblastine and ispinesib/vinblastine were assessed in 3 inde-
pendent TNBC cell lines using a 6  6 dose matrix including 5individual concentrations of the single compounds and all
their 25 dose pairs. Cell growth inhibition in MDA-MB-231,
MDA-MB-468, and BT-549 cells was illustrated in surface plots
and pointed towards an increased effect of the combination
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(Supplementary Figure 4). Determining the EOHSA allowed
for identification of combination effects exceeding the most
effective single agent (Figure 3A). In MDA-MB-231 cells for
example, combination treatment withmonastrol and vinblas-
tine exceeded cell growth inhibition compared to individual
compounds for all but the combinations including high con-
centrations of vinblastine. The combination ispinesib/vinblas-
tine was even more effective in this cell line and all 25 dose
pairs exceeded cell growth inhibition compared to individual
compounds. Quantitative assessment of combination effects
using the CI theorem confirmed synergistic interactions for
both combinations. On average more than 70% of the monas-
trol/vinblastine dose pairs synergistically inhibited TNBC cell
growth (CI< 0.9), of whichmore than 50% induced strong syn-
ergism (CI  0.3) (Figure 3 B). Antagonistic interactions were
mostly limited to either very high (MDA-MB-231 cells) or low
(MDA-MB-468 and BT-549 cells) compound concentrations.
Similar results were found for the combination ispinesib/
vinblastine, for which on average more than 65% of dose pairs
synergistically inhibited cell growth and more than 50%
thereof inducing strong synergism (Figure 3C). Here, synergis-
tic interactions were more prevalent in MDA-MB-231 and
MDA-MB-468 cells compared to BT-549 cells. Antagonistic ef-
fects were mainly observed for combinations with either very
low or high compound concentrations.
In sharp contrast with the effects observed in TNBC cells,
ispinesib and vinblastine alone or in combination only
induced a modest reduction in normal cell viability with a
maximum of 20% inhibition (Figure 3D). The surface plot of
the EOHSA indicated that dose pairs were predominantly
antagonistic in normal fibroblasts, especially for higher com-
pound concentrations, which were synergistic in TNBC cells
(Figure 3E).
3.4. Synergism of vinblastine and KSP/Eg5 inhibitors is
associated with increased mitotic arrest and apoptosis
induction
Both vinblastine and KSP/Eg5 inhibitors were reported to
induce mitotic arrest (Mayer et al., 1999; Pasquier and
Kavallaris, 2008). We therefore investigated the impact of
these compounds used alone and in combination on the cell
cycle distribution ofMDA-MB-231 cells. Cell cycle profiles indi-
cated an increase in the percentage of cells in G2/M phase af-
ter 24 h of treatment with the combination in comparison to
control cells, and cells treated with single vinblastine or ispi-
nesib (Figure 4A). Precisely, treatment with 0.32 nM ispinesibFigure 3 e Combination effects of KSP/Eg5 inhibitors and vinblastine on
combination treatments were tested for 25 concentration pairs 72 h post-tre
(EOHSA) show the difference in cell growth inhibition between KSP/EG5
treatment at the corresponding concentration in three independent TNBC
greater effect of the combination compared to single agents. (B, C) Dot plo
monastrol/vinblastine and ispinesib/vinblastine for all 25 concentration pa
method. (D) Surface plots showing the cell viability of MRC-5 fibroblasts
Single compound concentrations are denoted on the x- and y-axis, and cell
the Excess Over Highest Single Agent (EOHSA) shows the difference in ce
potent single treatment at the corresponding concentration in MRC-5 cellcombined with 0.5 nM vinblastine significantly enhanced the
G2/M arrest (46.0  12.8%) compared to no treatment
(17.3  2.2%, p < 0.0001), ispinesib (18.4  2.2%, p < 0.0001) or
vinblastine (29.7  6.3%, p < 0.01) only treatment (Figure 4B).
Similar results were obtainedwith the combination ofmonas-
trol and vinblastine (Supplementary Figure 5).
The mechanism leading to a G2/M arrest differs between
the compounds, with KSP/Eg5 inhibitors inducing the forma-
tion of monopolar mitotic spindles (Mayer et al., 1999), while
vinblastine blocks cells at the metaphase to anaphase transi-
tionwith eithermonopolar, bipolar ormultipolarmitotic spin-
dles (Ngan et al., 2001). To further decipher the combination
mechanism, we assessed the induction of mitotic arrest and
formation of mitotic spindles following single or combination
treatment using immunofluorescence staining of microtu-
bules. Figure 4C shows representative fluorescent images of
MDA-MB-231 cell microtubules and DNA 24 h post-
treatment. Exposure to 4nMvinblastine inducedmitotic arrest
at the metaphase to anaphase transition with either monopo-
lar or bipolar spindles. In comparison, mitotic arrest induced
by ispinesib (4 nM) and the combination was characterised
exclusively by the formation of monopolar mitotic spindles.
Quantification of fluorescent images confirmed that the
mitotic arrest induced by the combination was driven by the
formation ofmonopolar spindles rather than an increase in bi-
polar spindles (Figure 4D), thus suggesting that vinblastine
enhanced the ispinesib-induced phenotype.
The mitotic arrest of malignant cells is frequently associ-
ated with apoptotic cell death. Here, treatment of MDA-MB-
231 cells with ispinesib (0.32 nM) and vinblastine (0.5 nM) in
combination induced a 2.1e3.1-fold increase in apoptosis in-
duction (27.2  1.8%, p < 0.0001) as compared to untreated
control (8.9  1.0%, p > 0.05), vinblastine (13.1  1.3%) or
0.32 nM ispinesib (12.2  2.9%) alone (Figure 4E and F). Alto-
gether, these findings proved that the combination treatment
substantially enhanced apoptotic cell death in TNBC cells, as a
result of a mitotic arrest.
3.5. Vinblastine synergizes with KSP/Eg5 inhibitors in
an orthotopic model of TNBC
To investigate the in vivo antitumour activity in an orthotopic
xenograft model of TNBC, tumor-bearing nude mice were
treatedwith vehicle control, vinblastine alone (1mg/kg), ispine-
sib alone (5 mg/kg), or their combination once a week for 3
weeks. Over the 8 week study period, no significant weight
loss (>20%of thebodyweight)wasobserved inanyof thegroups
and mice constantly gained weight (Figure 5A). Administrationthe growth of TNBC cells and normal fibroblasts. Effects of
atment. (A, B) Surface plots of the Excess Over Highest Single Agent
inhibitors/vinblastine in combination and the most potent single
cell lines. Shades of blue depict positive values and thus stand for a
t representations of the combination index (CI) for the combinations
irs each. CI values were calculated following the Chou and Talalay
after treatment with ispinesib/vinblastine alone or in combination.
viability is plotted on the z-axis relative to control. (E) Surface plot of
ll viability between ispinesib/vinblastine in combination and the most
s.
Figure 4 e Combination effects of ispinesib and vinblastine on cell cycle, mitotic spindle and apoptosis induction. (A) Representative cell cycle
profiles of MDA-MB-231 cells incubated for 24 h with 0.5 nM vinblastine (red), 0.32 nM ispinesib (orange), or the combination (blue) measured
using PI staining, and (B) quantification of the fraction of cells arrested in G2/M phase. Columns, means of at least 3 individual experiments; Bars,
SD. Statistical analysis was performed using one-way ANOVA (**p < 0.01, ***p < 0.001). (C) Representative photographs of fluorescent staining
of microtubules and nuclei in MDA-MB-231 cells 24 h post-treatment with 4 nM of ispinesib or vinblastine or their combination. Arrows and
arrowheads denote mitotic cells with monoploar and bipolar spindles, respectively. Scale bars, 20 mm. (D) Quantification of mitotic cells with
monopolar or bipolar mitotic spindles. Columns, average of at least 350 cells; Bars, SD. Statistical analysis was performed by comparing the number
of mitotic cells with bipolar spindles using one-way ANOVA (****p < 0.0001). (E) Representative flow cytometry profiles of MDA-MB-231 cells
and (F) quantification of apoptotic cells after 48 h treatment with 0.32 nM ispinesib and 0.5 nM vinblastine alone or in combination measured
using Annexin V-FITC and PI staining. Columns, means of at least 3 individual experiments; Bars, SD. Statistical analysis was performed using
one-way ANOVA (***p < 0.001).
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Figure 5 e Change in animal weight and antitumour effect in vivo. Nude mice (BALB/c) were injected with 1*106 MDA-MB-231 cells to establish
an orthotopic TNBC model. Treatment with ispinesib (5 mg/kg) and Vinblastine (1 mg/kg) alone or in combination was initiated when the mean
tumour volume reached about 70 mm3 and was administered i.p. weekly for three weeks. Mice were monitored for a period of 8 weeks. (A) Change
in animal weights for the untreated control and treatment groups. (B) Antitumour effect of combination treatment and single treatments.
Statistical analysis of the tumor volume between vinblastine only and the combination treatment was performed using the Student’s t-test
(*p < 0.05). Points, mean values for 8 mice per group; Bars, SE.
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side effects and was therefore well tolerated. Importantly, the
synergism between vinblastine and ispinesib observed in vitro
was reflected in vivo by an increased antitumour activity of the
combination compared to single treatments (Figure 5B). From
week 5 onwards, combination treatment significantly reduced
tumour growth in mice, compared to control and single treat-
ments (Supplementary Figure 6). At study completion, the
tumour volume of the control group was on average
392  299 mm3, those in the ispinesib and vinblastine only
treated groupswere 422 244mm3 and 304 138mm3, respec-
tively, while that of the combination treated groupwas reduced
to 197  90 mm3. In summary, combination treatment signifi-
cant delayed tumor growth by 49.8% ( p < 0.05), 53.4%
( p< 0.01), and35.3% ( p< 0.05) compared to vehicle control, ispi-
nesib and vinblastine alone, respectively, confirming the
enhanced antitumour activity against TNBC in vivo.4. Discussion
Chemotherapeutic regimens consisting of multiple drugs
improve therapeutic outcome and can overcome drug resis-
tance (Dancey and Chen, 2006; Ramaswamy, 2007). However,
most combinations currently used in the clinic have been
developed through trial and error and this approach is expen-
sive and is often met with limited success. To facilitate the
rational design of combination chemotherapy regimens effec-
tive against drug-refractory tumours such as TNBC, we devel-
oped methodology based on high-content imaging and
multivariate drug profiling. Our workflow integrated fluores-
cencemicroscopy, automatic image segmentation, andmulti-
variate compound profiling, followed by evaluation of
combination effects, and led to the identification of synergis-
tic interactions that were validated in a preclinical model of
TNBC.
Biological systems acquire robustness to external pertur-
bations through several principles including systems control,
redundancy and ‘fail-safe-mechanism’ (Kitano, 2004, 2007). In
cancer cells this robustness is facilitated by genetic and epige-
netic modifications. The resulting compensationmechanismsoften bypass the effect of single drugs and are the reasons for
the failure of these single-drug treatments in complex disease
such as cancer (Hartman et al., 2001; Jia et al., 2009; Kitano,
2007). Optimized multi-component therapies can surmount
these defence mechanisms and are often used in clinic
(Baguley and Kerr, 2002; Jia et al., 2009; Ramaswamy, 2007).
Three mechanisms involved in triggering synergistic drug in-
teractionswere proposed. The first assumption is that compo-
nents of drug cocktails act on the same pathway and therefore
amplify the effect observed for single drug treatment. Sec-
ondly, compensatory mechanisms, which neutralise the ef-
fect of a single drug, are disabled by the diversity of the drug
combinations. And the third possibility is that drugs of a com-
bination act on different molecules or mutation sites to avoid
cross-resistance (Kitano, 2007). Systems-oriented approaches
are promising tools to develop such drug combinations. We
explored the approach of combining compounds depending
on the dissimilarities between the induced phenotypes.
Phenotypic alterations are caused by the interruption of sig-
nalling pathways, which translates into changes in cell prolif-
eration, morphology, and survival (Megason and Fraser, 2007).
Here, we hypothesised that compounds inducing either very
similar or dissimilar profiles have the potential to interact
synergistically. Combinations of compounds with similar
phenotypic effect can either amplify the inhibition of a single
target or overcome compensatory mechanisms. Such com-
pounds potentially act in the same or inter-connected path-
ways, or else interfere at different nodes in a pathway with
a common downstream target. We found that compound
pairs vinblastine/cytochalasin D, SB203580/SC560, and cyclo-
heximide/cytochalasin D induced similar phenotypes and
synergistically inhibited TNBC cell growth. As an example,
vinblastine/cytochalasin D in combination might counteract
compensatory mechanisms, such as accumulation of actin
stress fibres induced by microtubule depolymerization
(Enomoto, 1996; Pasquier et al., 2010) and reciprocally micro-
tubule polymerization following disruption of actin filaments
(Uematsu et al., 2007). In contrast, compounds that act on in-
dependent targets and thus entail the simultaneous disrup-
tion of diverse pathways are likely to induce different
phenotypes. The disruption of several cellular pathways
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interaction of the combination. An example is the compound
pair of FDA-approved chemotherapeutics doxorubicin and
vinblastine, which are part of the standard of care for Hodg-
kin’s lymphoma (Bonadonna et al., 1975) and were here found
to induced synergistic TNBC cell growth inhibition. Although
not all possible pair-wise combinations were examined in
the present study, our results showed that compound pairs
with either very similar or dissimilar profiles synergistically
inhibited TNBC cell growth.
Despite being likely to have major clinical implications,
many anti-cancer drug combinations have not been pre-
clinically studied for the nature of their interaction or the de-
pendencies of synergistic interactions (Chabner and Longo,
2006; Dancey and Chen, 2006), even though this type of inter-
action is known to be limited (Mayer and Janoff, 2007). In this
study, the combination of Eg5/KSP inhibitors with vinblas-
tine was selected for thorough analysis in TNBC models, as
its synergistic interaction was the most potent compared to
that of other tested compound pairs. Vinblastine is a
microtubule-targeting anticancer agent, which interferes
with microtubule dynamics, causing mitotic arrest and sub-
sequent apoptotic cell death (Jordan and Wilson, 2004). It is
used for the treatment of a broad range of cancers (Jackson
et al., 2007; Jordan and Wilson, 2004), and was reported to
have anticancer activity in pretreated patients with locally
advanced and metastatic breast cancer (Ospovat et al.,
2009). KSP/Eg5 inhibitors also cause mitotic arrest, which is,
however, elicited by failure of bipolar microtubule spindle
formation (Leizerman et al., 2004). The potential of KSP/Eg5
as an anticancer target was identified following the discovery
of monastrol (Mayer et al., 1999), which prompted further
development of this class of inhibitors (Rath and Kozielski,
2012). In the clinic, patients suffering from locally advanced
or metastatic breast cancer showed promising response
following the administration of ispinesib alone (Miller
et al., 2005), or in combination with chemotherapeutic agents
(Rodon et al., 2006). We found that synergistic interactions of
KSP/Eg5 inhibitors and vinblastine were sustained for
different doses and independent of the different sensitivities
of TNBC cell lines to the single compounds. BT-549 cells were
previously reported to be less sensitive to KSP/Eg5 inhibitors
as compared to MDA-MB-231 and MDA-MB-468 cells (Purcell
et al., 2010). This is important considering the cellular het-
erogeneity of tumours (Ramaswamy, 2007).
The synergism likely originates from the simultaneously
induced, yet distinct mechanisms responsible for mitotic ar-
rest and subsequently apoptotic cell death. Pritchard et al.
explored different types of mechanisms involved in drug in-
teractions and proposed that synergism was associated with
the enhancement of a single-compound drug mechanism of
action (Pritchard et al., 2013). This is in agreement with our
finding that the ispinesib-induced phenotype (i.e. formation
of monopolar mitotic spindle) is enforced through the addi-
tion of vinblastine leading to a significantly increased mitotic
arrest and apoptosis induction compared to single compound
treatments.
Synergistic interactions of drug combinations are only of
clinical importance if their antitumour effect exceeds general
toxicity and adverse synergistic effects observed in normaltissue (Ocana et al., 2012). We found that the synergistic inter-
action between ispinesib and vinblastine in rapidly dividing
malignant TNBC cells was not translated into increased cyto-
toxicity in a model of normal fibroblasts. This might be asso-
ciated with the greater selectivity of combinations compared
to individual drugs and the dependence of synergistic interac-
tions on pathways and cellular processes facilitating profit-
able drug interactions (Lehar et al., 2009). In support of our
in vitro findings, the combination of ispinesib and vinblastine
was not only well tolerated in vivo, but also showed enhanced
antitumour activity as compared to single treatments. Alto-
gether, these results demonstrate that the combination of
KSP/Eg5 inhibitors with microtubule targeting agents has
strong therapeutic potential and may lead to clinical benefits
in TNBC patients.5. Conclusion
In summary, integrating image-based drug profiling and anal-
ysis coupled with rigorous experimental in vitro and in vivo
validation can be used to discover new drug combinations
for TNBC and other drug-refractory cancers. Drug profiling
therefore represents a valid tool for the rapid and cost effec-
tive identification of synergistic drug combinations, and has
broad applicability in a range of cancers to prioritize drug
combinations for clinical trials.Acknowledgements
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